All GLG News Analyses Filed Under: Endocrinology
Posted December 26, 2007
Galapagos announces osteoporosis collaboration with Lilly
Analysis of: Galapagos announces osteoporosis collaboration with Lilly | www.pipelinereview.com
Author: GLG Member Program Contributor
Analysis of: Galapagos announces osteoporosis collaboration with Lilly | www.pipelinereview.com
Author: GLG Member Program Contributor
The collaboration between Galapagos NV (Euronext & LSE: GLPG) and Eli Lilly and Company (NYSE:LLY) is expected to show significant progress to develop bone formation for the treatment of osteoporosis at a global level. The news published in the www.pipeline.review shows the complimentary functions...
Posted December 17, 2007
Diabetes drug link to weak bones
Analysis of: Diabetes drug link to weak bones | news.bbc.co.uk
Author: GLG Member Program Contributor
Analysis of: Diabetes drug link to weak bones | news.bbc.co.uk
Author: GLG Member Program Contributor
Avandia needs definitive studies of its safety to ressurect itself. This study leads to a further reason for no longer using it. People may disagree, but those of us on the front lines are hard pressed using a drug with so much liability baggage.
Posted December 17, 2007
Dexcom says gets FDA OK to calibrate glucose monitoring system
Analysis of: Dexcom says gets FDA OK to calibrate glucose monitoring system | www.reuters.com
Author: GLG Member Program Contributor
Analysis of: Dexcom says gets FDA OK to calibrate glucose monitoring system | www.reuters.com
Author: GLG Member Program Contributor
Dexcom is really the leader of the pack of the glucose sensors, in a variety of ways. For such a small company to be in the lead, is quite impressive.
Posted December 10, 2007
Diabetes drug link to weak bones
Analysis of: Diabetes drug link to weak bones | news.bbc.co.uk
Author: GLG Member Program Contributor
Analysis of: Diabetes drug link to weak bones | news.bbc.co.uk
Author: GLG Member Program Contributor
This makes it easier for me to avoid mention or suggestion to my patients to try glitazones. I am having an easier time now with prior approvals of Januvia after only a trial of Metformin and sulfonylureas
Posted December 7, 2007
Diabetes drug link to weak bones
Analysis of: Diabetes drug link to weak bones | news.bbc.co.uk
Author: GLG Member Program Contributor
Analysis of: Diabetes drug link to weak bones | news.bbc.co.uk
Author: GLG Member Program Contributor
Using animal models, this article has undoubtedly shown the severe consequences of long-term use of Avadia for patients with type 2 diabetes. This news is adding further to the negative effects of Avadia found in previous evidence that the usuage of Avandia is linked to heart disease. The article has...
Posted December 7, 2007
Diabetes drug link to weak bones
Analysis of: Diabetes drug link to weak bones | news.bbc.co.uk
Author: GLG Member Program Contributor
Analysis of: Diabetes drug link to weak bones | news.bbc.co.uk
Author: GLG Member Program Contributor
-the relationship between avandia and ostoeporosis -implcations in clinical practice -implications for the future of avandia
Posted December 4, 2007New Avandia Study Will Do Little To Tip The Scale Against GSK Drug
Analysis of: Diabetes drug link to weak bones | news.bbc.co.uk
Author: Jeff Stier, Associate Director American Council on Science and Health
GlaxoSmithKline's Avandia is already under scrutiny, but the latest study will do little to tip the scale in terms of the risk/benefit analysis required before taking any medication.
Posted December 3, 2007
Study Shows Weight-Loss Drug Rimonabant is Associated with Severe Adverse Psychiatric Events
Analysis of: Study Shows Weight-Loss Drug Rimonabant is Associated with Severe Adverse Psychiatric Events | pharmalive.com
Author: GLG Member Program Contributor
Analysis of: Study Shows Weight-Loss Drug Rimonabant is Associated with Severe Adverse Psychiatric Events | pharmalive.com
Author: GLG Member Program Contributor
This drug did not come to market originally because of these concerns. This study only confirms that reasoning for not approving this agent.
Posted December 3, 2007
GlaxoSmithKline revises US labeling for Avandia
Analysis of: GlaxoSmithKline revises US labeling for Avandia | www.pipelinereview.com
Author: GLG Member Program Contributor
Analysis of: GlaxoSmithKline revises US labeling for Avandia | www.pipelinereview.com
Author: GLG Member Program Contributor
Considering all the controversy- whether right or wrong- the clinican will be hard-pressed to rx this agent with in our present medicolegal climate.
Posted November 28, 2007
Study Shows Weight-Loss Drug Rimonabant is Associated with Severe Adverse Psychiatric Events
Analysis of: Study Shows Weight-Loss Drug Rimonabant is Associated with Severe Adverse Psychiatric Events | pharmalive.com
Author: GLG Member Program Contributor
Previous
Page :
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 Next81 to
90
of 341Analysis of: Study Shows Weight-Loss Drug Rimonabant is Associated with Severe Adverse Psychiatric Events | pharmalive.com
Author: GLG Member Program Contributor
Rimonabant was studied for approval to exclude individuals with psychiatric disorders.
Now, it is found that there is a link associated with rimonabant and severe psychiatric disorders to include increase risk of suicide.
More GLG News in
Healthcare
Most Popular:
Source Article | Expert Analyses
FDA Approves EVOLENCE®, a New Generation Collagen-Based Facial Filler
www.investor.jnj.com
Longer Lashes in a Tube? Maybe Not
www.nytimes.com
Medicare fees to doctors fall Tuesday
news.yahoo.com
Doctors Say Medication Is Overused in Dementia
www.nytimes.com
Why anaesthetics can make the pain worse
www.newscientist.com
An illegal use of Lumigan, now legal?
July 3, 2008
How are we to pay for computers with a 10% drop in Medicare fees?
June 30, 2008
Obesity: Higher Healthcare Costs, Lower Productivity
June 26, 2008
Best acne care product I've seen.
June 25, 2008
Jeff is in accounting not a healthcare provider.
June 23, 2008

